<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="publisher-id">pbio</journal-id><journal-title>PLoS Biology</journal-title><issn pub-type="ppub">1544-9173</issn><issn pub-type="epub">1545-7885</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pbio.0050248</article-id><article-id pub-id-type="publisher-id">07-PLBI-RA-0938R1</article-id><article-id pub-id-type="sici">plbi-05-10-04</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry</subject><subject>Immunology</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Homo (Human)</subject></subj-group></article-categories><title-group><article-title>BDCA2/Fc&#x0025b;RI&#x003b3; Complex Signals through a Novel BCR-Like Pathway in Human Plasmacytoid Dendritic Cells</article-title><alt-title alt-title-type="running-head">BDCA2/Fc&#x003b5;RI&#x003b3; Activates BCR-Cascade in Human pDCs</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rosen</surname><given-names>David B</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bover</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Gokuran</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Musheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lanier</surname><given-names>Lewis L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yong-Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">&#x0002a;</xref></contrib></contrib-group><aff id="aff1"><label>1</label> Department of Immunology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America </aff><aff id="aff2"><label>2</label> Department of Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America </aff><aff id="aff3"><label>3</label> Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, California, United States of America </aff><aff id="aff4"><label>4</label> Biomedical Sciences Graduate Program, University of California at San Francisco, San Francisco, California, United States of America </aff><aff id="aff5"><label>5</label> Cancer Research Institute, University of California at San Francisco, San Francisco, California, United States of America </aff><contrib-group><contrib contrib-type="editor"><name><surname>Akira</surname><given-names>Shizuo</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Osaka University, Japan</aff><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>wcao&#x00040;mdacc.tmc.edu</email> (WC); <email>yjliu&#x00040;mdacc.tmc.edu</email> (YJL). </corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2007</year></pub-date><volume>5</volume><issue>10</issue><elocation-id>e248</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2007</year></date></history><copyright-statement><bold>Copyright:</bold> &#x000a9; 2007 Cao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2007</copyright-year><abstract><p>Dendritic cells are equipped with lectin receptors to sense the extracellular environment and modulate cellular responses. Human plasmacytoid dendritic cells (pDCs) uniquely express blood dendritic cell antigen 2 (BDCA2) protein, a C-type lectin lacking an identifiable signaling motif. We demonstrate here that BDCA2 forms a complex with the transmembrane adapter Fc&#x0025b;RI&#x003b3;. Through pathway analysis, we identified a comprehensive signaling machinery in human pDCs, similar to that which operates downstream of the B cell receptor (BCR), which is distinct from the system involved in T cell receptor (TCR) signaling. BDCA2 crosslinking resulted in the activation of the BCR-like cascade, which potently suppressed the ability of pDCs to produce type I interferon and other cytokines in response to Toll-like receptor ligands. Therefore, by associating with Fc&#x0025b;RI&#x003b3;, BDCA2 activates a novel BCR-like signaling pathway to regulate the immune functions of pDCs.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><sec id="st1"><title/><p>Dendritic cells (DCs) are specialized sentinels in the immune system that detect invading pathogens and, upon activation, initiate immune responses. DCs express C-type lectin receptors on their surface, which facilitate antigen capture. A distinct population of DCs, called plasmacytoid DCs (pDCs), display an extraordinary ability to rapidly make huge amounts of antiviral interferon (IFN) against viral infections. Human pDCs uniquely express a C-type lectin named BDCA2 that potently regulates pDCs function, yet the mechanism of how BDCA2 transduces signals is unknown. We show here that BDCA2 forms a complex with the transmembrane adapter Fc&#x0025b;RI&#x003b3;. Using signaling pathway analysis, we discovered a comprehensive signaling machinery in human pDCs, similar to that which operates downstream of B cell receptors (BCRs), but distinct from the pathway involved in T cell receptor signaling. By associating with Fc&#x0025b;RI&#x003b3;, BDCA2 activates a novel BCR-like signaling pathway to regulate the immune functions of pDCs. Since several pDC receptors use this pathway to modulate IFN and cytokine responses, these findings will guide more studies on how pDCs are regulated. Such mechanisms may lead to potential therapeutic interventions in autoimmune diseases involving hyperactivated pDCs, such as systemic lupus erythematosus and psoriasis.</p></sec></abstract><abstract abstract-type="toc"><p>Plasmacytoid dendritic cells (pDCs) are renowned for their production of type 1 interferon in response to viral infection, which is signified by Toll-like receptor (TLR) activation. Here, blood dendritic cell antigen 2(BDCA2), a C-type lectin receptor expressed uniquely on pDCs, is shown to block the ultimate effectors of TLR signaling via a novel pathway.</p></abstract><counts><page-count count="11"/></counts><custom-meta-wrap><custom-meta><meta-name>citation</meta-name><meta-value>Cao W, Zhang L, Rosen DB, Bover L, Watanabe G, et al. (2007) BDCA2/Fc&#x0025b;RI&#x003b3; complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol 5(10): e248. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pbio.0050248">10.1371/journal.pbio.0050248</ext-link></meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Dendritic cells (DCs) are specialized sentinels in the immune system that detect invading pathogens and pathological damages of the host. Upon activation, DCs instruct appropriate and effective immune responses &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b001">1</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b003">3</xref>&#x0005d;. Their extraordinary ability to capture antigens (self or foreign) is largely mediated by the collective expression of C-type lectin receptors (CLRs) on the cell surface &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b004">4</xref>,<xref ref-type="bibr" rid="pbio-0050248-b005">5</xref>&#x0005d;. In mouse spleen, DC subsets display a discrete expression profile of C-type lectins&#x02014;CD8<sup>&#x0002b;</sup> DCs express DEC-205 (CD205), whereas CD8<sup>&#x02212;</sup> DCs express dendritic cell immunoreceptor 2 (DCIR2), dendritic cell immunoactivating receptor (DCAR), Dectin-1, Dectin-2, DCIR3, and DC-SIGN &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b006">6</xref>&#x0005d;. This expression profile, in conjunction with the polarized expression of antigen processing and presentation machinery, contributes to the intrinsic functional difference between the DC subsets in regulating immunity &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b006">6</xref>&#x0005d;. In humans, C-type lectin ICAM3-grabbing nonintegrin (DC-SIGN, CD209) is expressed by mucosal DCs and langerin (CD207) is expressed by Langerhans cells &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b003">3</xref>,<xref ref-type="bibr" rid="pbio-0050248-b004">4</xref>&#x0005d;. Besides tissue DCs, macrophage, myeloid DCs (mDCs) and monocytes express a number of CLRs, such as Dectin-1, macrophage mannose receptor (MMR), and DCIR &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b003">3</xref>,<xref ref-type="bibr" rid="pbio-0050248-b004">4</xref>&#x0005d;.</p><p>Plasmacytoid DCs (pDCs), also referred to as natural type I interferon (IFN)-producing cells (IPCs), are a distinct DC population with an extraordinary ability to rapidly produce massive amounts of type I IFN in response to viral infections &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b007">7</xref>,<xref ref-type="bibr" rid="pbio-0050248-b008">8</xref>&#x0005d;. Blood dendritic cell antigen 2 (BDCA2), a C-type lectin uniquely expressed on resting human pDCs, has been used to unequivocally identify pDCs in human peripheral blood and tissues &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b009">9</xref>&#x0005d;. It has an intracellular N terminus and only one extracellular carbohydrate recognition domain, which belongs to the type II C-type lectin group &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b005">5</xref>,<xref ref-type="bibr" rid="pbio-0050248-b010">10</xref>,<xref ref-type="bibr" rid="pbio-0050248-b011">11</xref>&#x0005d;. Similar to CLRs on other DC subsets, BDCA2 has been suggested to be capable of functioning as an antigen-uptake receptor, because monoclonal antibodies (mAbs) bound to BDCA2 on the surface of pDCs are efficiently internalized, and mAb-derived peptide bound to MHC class II can be presented to T cells &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b010">10</xref>&#x0005d;.</p><p>Resting pDCs uniquely express high amounts of Toll-like receptor 9 (TLR9) and TLR7 &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b012">12</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b014">14</xref>&#x0005d;, which recognize microbial DNA or RNA ligands in the endo-lysosomal compartment, respectively. After activation of TLR7 or TLR9, a multi-component &#x0201c;cytoplasmic transductional&#x02013;transcriptional complex&#x0201d; is formed to initiate cellular activations &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b015">15</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b017">17</xref>&#x0005d;. Type I IFN production by pDCs has been shown to be independent of RNA helicases retinoic acid&#x02013;inducible gene I <italic>(RIG-I)</italic>, melanoma differentiation-associated gene 5 <italic>(MDA5)</italic> and their adaptor IFN-&#x000df; promoter stimulator-1 <italic>(IPS-1)</italic> &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b015">15</xref>,<xref ref-type="bibr" rid="pbio-0050248-b018">18</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b020">20</xref>&#x0005d;, which are essential for IFN response to viruses by other immune or nonhematopoietic cells. Therefore, pDCs carry out their unique innate immune functions through the TLR-mediated pathway. After exposure to viruses, pDCs differentiate into efficient antigen-presenting DCs and thus act as a critical mediator linking innate and adaptive immune responses against viral infections &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b007">7</xref>,<xref ref-type="bibr" rid="pbio-0050248-b008">8</xref>&#x0005d;. However, aberrant pDC activation in the absence of infection has been associated with autoimmune diseases. Patients with active systemic lupus erythematosus (SLE) have high amounts of type I IFN in their sera, which is likely due to the activation of pDCs by autoantibodies complexed with self nuclear antigens &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b021">21</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b024">24</xref>&#x0005d;. Because both TLR7 and TLR9 are located intracellularly, how pDCs sense the extracellular microenvironment and, in turn, modulate these TLR-mediated responses remains an important question.</p><p>BDCA2 was the first receptor described that negatively regulates the IFN response of pDCs, which is induced by CpG oligonucleotide, influenza virus, or by autoantibodies complexed with DNA &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b025">25</xref>,<xref ref-type="bibr" rid="pbio-0050248-b026">26</xref>&#x0005d;. However, it is not clear how BDCA2 modulates the TLR signaling, because its cytoplasmic domain does not contain any known signaling motifs, even though BDCA2 ligation by mAbs causes protein tyrosine phosphorylation and calcium influx &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b025">25</xref>&#x0005d;. A recent analysis of the closely related dendritic cell immunoreceptor family lectins, which include DCIR, DCAR, Dectin-2, and BDCA2, suggests a potential shared signaling mechanism as a result of the similar arrangement of their transmembrane domains &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b011">11</xref>,<xref ref-type="bibr" rid="pbio-0050248-b027">27</xref>,<xref ref-type="bibr" rid="pbio-0050248-b028">28</xref>&#x0005d;. Both DCAR and Dectin-2 have been shown to associate with Fc&#x0025b;RI&#x003b3; to transduce cellular activation signals &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b029">29</xref>,<xref ref-type="bibr" rid="pbio-0050248-b030">30</xref>&#x0005d;.</p><p>Here we report that BDCA2 signals in pDCs by associating with the transmembrane adapter Fc&#x0025b;RI&#x003b3; and initiates an immunoreceptor-based tyrosine activation motif (ITAM)&#x02013;dependent signaling cascade. We also provide evidence that human pDCs express a series of signaling molecules known to be specifically involved in BCR activation. We demonstrate that the BDCA2 and Fc&#x0025b;RI&#x003b3; complex activates a prominent BCR-like signaling pathway in human pDCs to modulate the TLR-mediated responses.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>BDCA2 Associates with and Signals through Fc&#x0025b;RI&#x003b3;</title><p>To determine the expression profile of BDCA2 in human leukocytes, we searched our established gene expression database, which includes the major immune cell types in peripheral blood. Strikingly, BDCA2 transcripts were expressed abundantly and exclusively by human pDCs (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>A), consistent with its specific surface expression on pDCs within total peripheral blood mononuclear cell (PBMC) &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b009">9</xref>&#x0005d;. By contrast, immature peripheral blood CD11c<sup>&#x0002b;</sup> mDC, monocyte, and monocyte-derived DC (mono-DC) expressed transcripts of other C-type lectins, such as DC-SIGN, Dectin-1, DCIR, and MMR, which were absent in pDCs (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>A).</p><fig id="pbio-0050248-g001" position="float"><label>Figure 1</label><caption><title>BDCA2 Associates with Fc&#x0025b;RI&#x003b3; To Form a pDC-Specific Receptor Complex</title><p>(A) The expression profile of BDCA2 transcripts in peripheral blood leukocytes by microarray gene expression analysis is shown. In comparison, the relative expression levels of DC-SIGN, Dectin-1, DCIR, and MMR are also shown. A value of &#x0003c;1 (arbitrary units) indicates the absence of gene expression.</p><p>(B) Surface expression of BDCA2 after transduction of BDCA2 into Jurkat cells previously transfected with control, Fc&#x0025b;RI&#x003b3;, DAP12, DAP10, or a Y-F ITAM mutant Fc&#x0025b;RI&#x003b3;. The surface staining by isotype-matched control mAb is shown as a shaded area.</p><p>(C) Co-immunoprecipitation of BDCA2 and Fc&#x0025b;RI&#x003b3; from BDCA2 and Fc&#x0025b;RI&#x003b3; doubly transfected Jurkat cells after cell surface biotinylation. Western blot analysis was performed with anti-Fc&#x0025b;RI&#x003b3; Ab or with HRP-conjugated NeutrAvidin.</p><p>(D) Co-immunoprecipitation of BDCA2 and Fc&#x0025b;RI&#x003b3; from freshly isolated pDCs. Western blot analysis was performed with anti-Fc&#x0025b;RI&#x003b3; Ab.</p></caption><graphic xlink:href="pbio.0050248.g001"/></fig><p>pDCs express two transmembrane adapter proteins bearing ITAMs, i.e., Fc&#x0025b;RI&#x003b3; and DAP12, as well as DAP10, which signals via a YINM motif to activate PI3K &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;. To test whether BDCA2 interacts with any of these adapters, the individual adapters were first stably transduced into Jurkat cells, a human T cell line. When BDCA2 was transfected into Jurkat cells containing Fc&#x0025b;RI&#x003b3;, the expression of BDCA2 on the cell surface was greatly enhanced, indicating a potential interaction between BDCA2 and Fc&#x0025b;RI&#x003b3; (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>B). In contrast, the presence of DAP12 and DAP10 only marginally affected BDCA2 expression, whereas both DAP12 and DAP10 increased the surface expression of mouse NKG2D, used as a positive control &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;. The enhanced BDCA2 surface expression in the presence of Fc&#x0025b;RI&#x003b3; was also observed in several T and B cell lines (<xref ref-type="supplementary-material" rid="pbio-0050248-sg001">Figure S1</xref>). To demonstrate directly the physical association between BDCA2 and Fc&#x0025b;RI&#x003b3;, we performed co-immunoprecipitation experiments and showed that Fc&#x0025b;RI&#x003b3; existed in a complex that could be precipitated by antibody to BDCA2, but not by an isotype-matched control antibody from transfected Jurkat cells (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>C) and, furthermore, from freshly isolated human pDCs (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>D). These data suggest that BDCA2 and Fc&#x0025b;RI&#x003b3; form a receptor complex with signaling potential.</p><p>Previously, BDCA2-transfected Jurkat cells were shown to be unable to initiate protein tyrosine phosphorylation after BDCA2 crosslinking, an observation suggesting the potential involvement of a signaling adapter &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b025">25</xref>&#x0005d;. When BDCA2 was crosslinked on the Jurkat cells that were cotransfected with different adapters, Jurkat cells expressing Fc&#x0025b;RI&#x003b3;, but not DAP12 or DAP10, prominently phosphorylated a spectrum of proteins (<xref ref-type="fig" rid="pbio-0050248-g002">Figure 2</xref>A). We constructed a mutant Fc&#x0025b;RI&#x003b3; in which the tyrosine (Y) residue within the intracellular ITAM was replaced with phenylalanine (F), rendering it unable to recruit downstream molecules. This mutant Fc&#x0025b;RI&#x003b3; supported the elevated levels of surface expression of BDCA2 (<xref ref-type="fig" rid="pbio-0050248-g001">Figure 1</xref>B) but was unable to mediate the protein tyrosine phosphorylation after BDCA2 crosslinking (<xref ref-type="fig" rid="pbio-0050248-g002">Figure 2</xref>B), indicating an essential role of the ITAM in Fc&#x0025b;RI&#x003b3; for the signaling by the BDCA2/Fc&#x0025b;RI&#x003b3; complex.</p><fig id="pbio-0050248-g002" position="float"><label>Figure 2</label><caption><title>Crosslinking the BDCA2/Fc&#x0025b;RI&#x003b3; Complex Transduces Activation Signals</title><p>(A) Total protein phosphorylation in Jurkat cells transfected with BDCA2 in the absence or presence of adapter proteins by anti-BDCA2 mAb or control IgG1 crosslinking. Western blot analysis was performed with anti-phosphotyrosine mAb PY20.</p><p>(B) Total protein phosphorylation induced by anti-BDCA2 mAb crosslinking in Jurkat cells transfected with BDCA2 and wild-type (WT) or mutant (Y-to-F) Fc&#x0025b;RI&#x003b3;.</p><p>(C) Transfected mouse 2B4 T hybridoma cells with an NFAT-GFP reporter (transgenes are labeled on the top) were crosslinked with control mouse IgG1 or anti-BDCA2 mAb. Cells were analyzed for GFP expression by flow cytometry. Cells cultured in medium alone or with ionomycin (positive control) were also analyzed.</p><p>(D) The kinetics of intracellular calcium flux in transfected Jurkat cells (transgenes are labeled on top) when crosslinked (marked by arrow) by control (IgG1) or anti-BDCA2 mAb.</p></caption><graphic xlink:href="pbio.0050248.g002"/></fig><p>Furthermore, when a human BDCA2/Fc&#x0025b;RI&#x003b3; complex was introduced into a mouse T cell hybridoma line that contained an intracellular nuclear factor of activated T cells&#x02013;green fluorescent protein (NFAT-GFP) reporter construct &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>,<xref ref-type="bibr" rid="pbio-0050248-b032">32</xref>&#x0005d;, crosslinking BDCA2 by mAb resulted in GFP expression (<xref ref-type="fig" rid="pbio-0050248-g002">Figure 2</xref>C), indicating that the BDCA2/Fc&#x0025b;RI&#x003b3; receptor complex was able to activate NFAT, similar to the effect of TCR-induced activation. In the absence of Fc&#x0025b;RI&#x003b3;, crosslinking BDCA2 did not induce GFP expression (<xref ref-type="fig" rid="pbio-0050248-g002">Figure 2</xref>C). Finally, calcium influx, one of the important cellular activation events that occurs downstream of ITAM signaling, was effectively triggered by BDCA2 crosslinking in Jurkat cells transfected with both BDCA2 and Fc&#x0025b;RI&#x003b3;, but not in cells transfected with BDCA2 alone (<xref ref-type="fig" rid="pbio-0050248-g002">Figure 2</xref>D), further confirming the requirement of Fc&#x0025b;RI&#x003b3; for BDCA2 to signal.</p></sec><sec id="s2b"><title>Human pDCs Express Signaling Molecules Involved in BCR Activation</title><p>To further delineate the intracellular signaling events following BDCA2 and Fc&#x0025b;RI&#x003b3; activation, we examined the expression by pDCs of components known to be involved in ITAM-mediated signaling. In lymphocytes, several well-established signaling pathways exist downstream of the B cell and T cell antigen receptors, linked through ITAM-bearing subunits of these receptor complexes. We analyzed the expression of molecules involved in BCR and TCR activation in pDCs in comparison with peripheral B cells, T cells, natural killer (NK) cells, mDCs, and monocytes.</p><p>After receptor activation, two core tyrosine residues within the ITAM(s) are phosphorylated by Src family protein tyrosine kinases (PTKs). The phosphorylated tyrosines within the ITAMs associate with the src homology 2(SH2) domains of Syk-family PTKs, which in turn phosphorylate cell-type&#x02013;specific intracellular adapters to initiate a multitude of signaling events. Each type of lymphocyte expresses and uses a distinct set of proteins to carry out the receptor-proximal signal transduction &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b033">33</xref>,<xref ref-type="bibr" rid="pbio-0050248-b034">34</xref>&#x0005d;. B cells express B lymphoid tyrosine kinase (BLK), Lyn kinase, spleen tyrosine kinase (Syk), and two adapter molecules, BLNK and BCAP, whereas T cells preferentially use two other Src-family PTKs, Fyn and Lck, and CD3&#x003be;-associated protein kinase (ZAP-70) from the Syk-family of PTKs, as well as alternative adapters, i.e., SLP-76 and linker for activation of T cells (LAT) (<xref ref-type="fig" rid="pbio-0050248-g003">Figure 3</xref>A). Strikingly, pDCs express many members of the BCR signaling cascade, but not those involved in TCR activation (<xref ref-type="fig" rid="pbio-0050248-g003">Figure 3</xref>A). Of note, the levels of the B cell&#x02013;specific adapter B cell linker (BLNK, also known as SLP-65 or BASH) was transcribed at higher levels in pDC than in B cells (514 relative units versus 133 relative units, respectively). Another B cell adapter, BCAP, which mediates phosphoinositide-3-kinase (PI3K) signaling &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b035">35</xref>&#x0005d;, was also abundantly expressed by pDCs (<xref ref-type="fig" rid="pbio-0050248-g003">Figure 3</xref>A). pDCs expressed lower levels of BLK compared to B cells. Interestingly, NK cells, in addition to expressing several members of the TCR signaling pathway, were found also to express several molecules involved in BCR signaling, e.g., Lyn, Syk and BCAP. mDC and monocyte similarly express Lyn, Syk, BCAP, and Fyn as well as the T cell adaptor SLP76. However unlike pDCs and B cells, they both lack the expression of BLNK and BLK (<xref ref-type="fig" rid="pbio-0050248-g003">Figure 3</xref>A). Within all the peripheral cell leukocytes we examined, BLNK transcripts were only transcribed by pDCs and B cells (unpublished data).</p><fig id="pbio-0050248-g003" position="float"><label>Figure 3</label><caption><title>Human pDCs Express a BCR-Like Signaling Cascade</title><p>(A) Expression of genes encoding molecules involved in BCR (top panel) and TCR (bottom panel) signaling in six peripheral leukocyte cell types from microarray gene expression analysis.</p><p>(B) The relative gene expression of signaling molecules in different cell types from three healthy donors determined by quantitative RT-PCR analysis. The expression was normalized with the level of the transcript in total PBMC. The median expression is marked by a horizontal bar.</p><p>(C) The expression of signaling proteins in different cell types was determined by Western blot analysis. The results from one representative donor out of three healthy donors analyzed are shown.</p></caption><graphic xlink:href="pbio.0050248.g003"/></fig><p>We next analyzed the expression of the signaling components operating downstream of the molecules described above. pDCs and B cells selectively transcribed PLC&#x003b3;2, Vav2, and Vav3, which are absent in T cells (<xref ref-type="supplementary-material" rid="pbio-0050248-sg002">Figure S2</xref>). On the other hand, high levels of PKC&#x003b8; are abundantly expressed by T and NK cells, but not by pDCs or B cells (<xref ref-type="supplementary-material" rid="pbio-0050248-sg005">Figure S5</xref>). In contrast, the expression of other downstream signaling molecules, such as PI3K, Nck, MAP kinases, and NFAT, failed to show a distinct cell type&#x02013;specific pattern (<xref ref-type="supplementary-material" rid="pbio-0050248-sg002">Figure S2</xref>).</p><p>We confirmed the transcription and protein expression of the BCR proximal signaling molecules in pDCs from several healthy donors by RT-PCR and Western blot analysis (<xref ref-type="fig" rid="pbio-0050248-g003">Figure 3</xref>B and <xref ref-type="fig" rid="pbio-0050248-g003">3</xref>C). Taken together, our analysis revealed the existence of a potential ITAM-mediated signaling cascade in human pDCs similar to that of B cells, but distinct from that in T cells, NK cells, monocytes, or mDCs (<xref ref-type="fig" rid="pbio-0050248-g004">Figure 4</xref>).</p><fig id="pbio-0050248-g004" position="float"><label>Figure 4</label><caption><title>Diagram of ITAM-Mediated Signaling Pathways in Human Leukocytes</title><p>The schematic cascades that are involved in receptor proximal signaling (solid arrows) and those leading to NF-&#x003ba;B activation (dotted lines) are shown.</p></caption><graphic xlink:href="pbio.0050248.g004"/></fig></sec><sec id="s2c"><title>BDCA2/Fc&#x0025b;RI&#x003b3; Complex Transduces Signals via a BCR-Like Signaling Cascade</title><p>To investigate whether the BDCA2/Fc&#x0025b;RI&#x003b3; receptor complex could signal through the BCR signaling cascade, Namalwa cells, a human Burkitt lymphoma cell line, was transfected with BDCA2 and Fc&#x0025b;RI&#x003b3;. Similar to BCR activation, crosslinking of the BDCA2/Fc&#x0025b;RI&#x003b3; complex on Namalwa cells resulted in rapid phosphorylation of residue Y525 of Syk and residue Y416 of Src-family PTKs (<xref ref-type="fig" rid="pbio-0050248-g005">Figure 5</xref>). After BCR activation, five tyrosine residues on BLNK are phosphorylated, enabling its function as a scaffold to integrate and propagate signals to downstream proteins &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b036">36</xref>&#x0005d;. BDCA2 ligation resulted in phosphorylation of residue Y84 of BLNK (<xref ref-type="fig" rid="pbio-0050248-g004">Figure 4</xref>). Additional downstream molecules, such as Vav1 and PLC&#x003b3;2, were phosphorylated by BDCA2 crosslinking, similar to BCR activation (<xref ref-type="fig" rid="pbio-0050248-g005">Figure 5</xref>). MAP kinases Erk1/2, which are also activated after BCR engagement through the Ras-Raf pathway, were rapidly phosphorylated after BDCA2 stimulation (<xref ref-type="fig" rid="pbio-0050248-g005">Figure 5</xref>). Furthermore, we observed a robust Ca<sup>&#x0002b;&#x0002b;</sup> influx in Namalwa cells after BDCA2 crosslinking, which is dependent on Fc&#x0025b;RI&#x003b3; (unpublished data).</p><fig id="pbio-0050248-g005" position="float"><label>Figure 5</label><caption><title>BDCA2/Fc&#x0025b;RI&#x003b3; Complex Signals through the BCR Signaling Cascade in Transfected B Cells</title><p>Shown are the kinetics of tyrosine phosphorylation of BCR intracellular signaling components in transduced Namalwa cells when crosslinked by control IgG1 or anti-BDCA2 mAb in comparison with BCR activation by anti-human Ig Ab.</p></caption><graphic xlink:href="pbio.0050248.g005"/></fig><p>To study the signaling of the BDCA2/Fc&#x0025b;RI&#x003b3; complex in primary human pDCs, we crosslinked BDCA2 by mAbs on freshly isolated pDCs and confirmed that it potently induces a transient intracellular calcium flux (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>A). This activity was inhibited by PP2, a compound that inhibits Src family PTKs, but was not affected by an inactive control compound, PP3. In addition, Syk inhibitor completely abolished the intracellular calcium flux in BDCA2-crosslinked pDCs (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>A). These results suggest the functional involvement of both Syk and Src-family PTKs during BDCA2 signaling. When the phosphorylation status of key signaling molecules in pDCs was analyzed, BDCA2 crosslinking resulted in rapid phosphorylation of both Src family PTKs and Syk (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>B), indicating the onset of ITAM-induced signaling in pDCs. Different from the results with the Namalwa cell line, BDCA2 crosslinking did not enhance the pre-existing phosphorylation of BLNK in pDCs (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>B, lane 5). High levels of phosphorylation of Y84 in the BLNK protein have been observed in freshly isolated, resting pDCs from several healthy donors, but not in freshly isolated human B cells (unpublished data). Moreover, downstream molecules, including Vav1, PLC&#x003b3;2, and Erk1/2, were phosphorylated by BDCA2 crosslinking on pDCs (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>B). In contrast, crosslinking with neither the isotype-matched control antibody nor the mAb against BDCA-4, another surface molecule expressed on pDCs, phosphorylated these proteins under the same conditions (<xref ref-type="fig" rid="pbio-0050248-g006">Figure 6</xref>B). It should be noted that BDCA-4 beads were used to isolate pDCs, therefore BDCA-4 may no longer available for efficient crosslinking. The Src PTK inhibitor PP2 or Syk inhibitor, but not PP3, greatly diminished BDCA2-induced phosphorylation of both Src family PTKs and Syk and blocked the phosphorylation of Vav1 and PLC&#x003b3;2 (<xref ref-type="supplementary-material" rid="pbio-0050248-sg003">Figure S3</xref>). Thus, the BDCA2/Fc&#x0025b;RI&#x003b3; complex signals through a BCR-like signaling cascade in primary human pDCs.</p><fig id="pbio-0050248-g006" position="float"><label>Figure 6</label><caption><title>BDCA2/Fc&#x0025b;RI&#x003b3; Complex Signals through a BCR-Like Signaling Cascade in Primary pDCs</title><p>(A) The kinetics of intracellular calcium flux in freshly isolated pDCs when crosslinked (marked by arrow) by control IgG1 or anti-BDCA2 Ab. As indicated, cells were pre-incubated with PP2, PP3, or Syk inhibitor prior to crosslinking.</p><p>(B) The kinetics of tyrosine phosphorylation on BCR intracellular signaling components in freshly isolated pDCs when crosslinked by control IgG1, anti-BDCA2 mAb, or anti-BDCA-4 mAb.</p></caption><graphic xlink:href="pbio.0050248.g006"/></fig></sec><sec id="s2d"><title>BDCA2/Fc&#x0025b;RI&#x003b3; Complex Signaling Inhibits TLR-Mediated Type I IFN Production</title><p>Although BCR signaling synergizes with TLR triggering for optimal B lymphocyte activation &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b037">37</xref>&#x0005d;, the impact of this pathway on TLR-mediated type I IFN responses needs to be defined. To accomplish this, we stably transfected human Burkitt lymphoma Namalwa cells with IRF7, BDCA2 and Fc&#x0025b;RI&#x003b3;. These cells with endogenous TLR9 expression &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b038">38</xref>&#x0005d; produced IFN&#x003b1; in response to stimulation with CpG oligonucleotide (ODN) (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>A). Crosslinking of BDCA2/Fc&#x0025b;RI&#x003b3; or BCR together with CpG activation in these Namalwa cells resulted in enhanced interleukin 10 (IL-10) production, as expected, but decreased IFN&#x003b1; secretion (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>A), indicating a selective suppressive effect by BCR or BDCA2 activation on TLR-induced IFN&#x003b1; production.</p><fig id="pbio-0050248-g007" position="float"><label>Figure 7</label><caption><title>Ligation of the BDCA2/Fc&#x0025b;RI&#x003b3; Complex Inhibits TLR-Induced Type I IFN Production</title><p>(A) Transfected Namalwa cells were stimulated with CpG ODN and ligated with anti-BDCA2, anti-BCR, or control mAbs. Shown are the amounts of IFN&#x003b1; and IL-10 secreted by the cells stimulated CpG in a triplicate assay.</p><p>(B) Purified pDCs were stimulated by CpG (top panel) or R848 (bottom panel) following anti-BDCA2 or control mAb crosslinking. The amounts of the secreted IFN&#x003b1;, TNF&#x003b1;, and IL-6 in a triplicate assay from a representative donor (<italic>n</italic> &#x02265; 3) are shown.</p><p>(C) Purified pDCs stimulated by CpG first and then treated with anti-BDCA2 or control mAbs at different time intervals. The amounts of the secreted IFN&#x003b1;, TNF&#x003b1;, and IL-6 from a representative donor (<italic>n</italic> &#x02265; 3) are shown.</p><p>(D) The amounts of type I IFN transcripts were determined by quantitative RT-PCR analysis. The expression is shown as the relative level of transcription compared with unstimulated PBMC.</p></caption><graphic xlink:href="pbio.0050248.g007"/></fig><p>To investigate the function of the BCR-like signaling cascade in pDCs, we analyzed, in detail, the impact of BDCA2 crosslinking on the innate immune responses of human primary pDCs. Purified pDCs were stimulated with CpG ODN 2216 or R848, ligands of TLR9 and TLR7 or TLR8, respectively, in the presence of anti-BDCA2 mAb or control mAbs. BDCA2 ligation potently inhibited IFN&#x003b1; production and invariably reduced the production of tumor necrosis factor &#x003b1; (TNF&#x003b1;) and IL-6 induced by stimulation with these TLR ligands (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>B). pDCs secreted lower levels of IFN&#x003b1; after BDCA2 ligation, but normal amounts of chemokines CXCL10/IP-10, CCL3/MIP-1&#x003b1; and CCL4/MIP-1&#x003b2; in response to CpG (<xref ref-type="supplementary-material" rid="pbio-0050248-sg004">Figure S4</xref>).</p><p>To evaluate the kinetics of BDCA2-mediated suppression of IFN production, pDCs were first stimulated with CpG and control or anti-BDCA2 mAbs were added to the culture at different times afterward. Strikingly, up to 4 h after pDCs were exposed to CpG ODN, crosslinking BDCA2 by mAb effectively inhibited IFN&#x003b1; and cytokine production by pDCs (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>C). This result demonstrates the potency of BDCA2 to inhibit the TLR-induced innate immune responses by pDCs. Independently, pDCs from multiple donors were stimulated simultaneously with both CpG and anti-BDCA2 or control mAbs and at different lapsed times, the amounts of IFN&#x003b1; in the supernatant were measured (<xref ref-type="supplementary-material" rid="pbio-0050248-sg005">Figure S5</xref>). At 4 h after CpG treatment, pDCs treated with anti-BDCA2 mAbs reduced the production of IFN&#x003b1; by 96&#x00025;. By 8 h post CpG treatment, BDCA2-ligated pDCs produced an average of 25.6&#x00025; of IFN&#x003b1; compared to the amount made by control IgG1-incubated pDCs (<xref ref-type="supplementary-material" rid="pbio-0050248-sg005">Figure S5</xref>). Therefore, BDCA2 crosslinking likely blocked the initial induction of IFN&#x003b1; secretion.</p><p>To further determine the stage of IFN suppression, we measured the amount of type I IFN transcripts from CpG-activated pDCs that were crosslinked with anti-BDCA2 or control mAbs. BDCA2 crosslinking uniformly reduced the transcription of all the subtypes of type I IFN analyzed, i.e., IFN&#x003b1;, IFN&#x003b2;, IFN&#x003b3;, and IFN&#x003c9; (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>D). Therefore, BDCA2 ligation blocks the transcriptional of type I IFN by pDCs in response to TLR activation.</p></sec></sec><sec id="s3"><title>Discussion</title><p>To date, BDCA2 is the only C-type lectin that is found expressed exclusively on human pDCs, and it serves as a defining marker for pDCs. In addition, BDCA2 represents one of the most potent receptors that modulates the ability of pDCs to elicit type I IFN responses. Here we provide experimental evidence to reveal the signaling mechanism used by BDCA2 in human pDCs. On the cell surface, BDCA2 associates with Fc&#x0025b;RI&#x003b3; to form a signaling receptor complex, which, upon ligation, activates a novel BCR-like intracellular signaling cascade, interfering with TLR activation.</p><p>ITAM-based signaling is the primary pathway of activation used by classical immunoreceptors, such as the antigen receptors on B and T lymphocytes, NK cell receptors, and the Fc receptors on myeloid cells &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b039">39</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b041">41</xref>&#x0005d;. ITAM-mediated signaling is also used by additional receptors, such as cell adhesion molecules, chemokine receptors, plexins, and lectin receptors &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b042">42</xref>&#x0005d;. pDC and mDCs represent two major subsets of professional antigen-presenting cells in human peripheral blood and tissues, which use different sets of pattern recognition receptors, such as TLRs, CLRs, and Nod-like receptors, for sensing and responding to microbial infections &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b043">43</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b050">50</xref>&#x0005d;. Our present study suggests that mDCs and pDCs not only express different repertories of lectin receptors, but also suggests that the signal pathways used by CLRs bearing ITAM elements on mDC and pDCs are intrinsically different. Ligation of either the BDCA2/Fc&#x0025b;RI&#x003b3; complex or certain myeloid cell lectins, such as Dectin-1 and DC-SIGN &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b051">51</xref>,<xref ref-type="bibr" rid="pbio-0050248-b052">52</xref>&#x0005d;, phosphorylates Syk, which is involved in BCR membrane-proximal signaling. However, downstream of Syk, pDCs use the intracellular adaptor molecule BLNK, whereas mDCs use SLP76 for amplification of signaling (<xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>). In addition, recent studies showed that CARD9, a signaling adaptor molecule, plays a critical role in the signal transduction of Dectin-1 and ITAM-associated receptors in myeloid cells &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b053">53</xref>,<xref ref-type="bibr" rid="pbio-0050248-b054">54</xref>&#x0005d;. Our analysis suggests that similar to lymphocytes, pDCs do not express CARD9, but likely use CARMA1 (also named CARD11) to activate nuclear factor &#x003ba;B (NF-&#x003ba;B) &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b055">55</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b057">57</xref>&#x0005d; (<xref ref-type="supplementary-material" rid="pbio-0050248-sg006">Figure S6</xref> and <xref ref-type="fig" rid="pbio-0050248-g007">Figure 7</xref>).</p><p>Previous studies have shown remarkable similarities between B lineage cells and pDCs, including their plasma cell morphology and shared expression of several classes of genes. For example, they express a similar sets of TLRs (TLR7 and TLR9) &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b012">12</xref>,<xref ref-type="bibr" rid="pbio-0050248-b014">14</xref>,<xref ref-type="bibr" rid="pbio-0050248-b058">58</xref>&#x0005d;, possess germ-line immunoglobulin (Ig) transcripts and Ig recombinase &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b059">59</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b061">61</xref>&#x0005d;, have B cell&#x02013;related transcription factor Spi-B &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b059">59</xref>,<xref ref-type="bibr" rid="pbio-0050248-b062">62</xref>&#x0005d;, and use the same CIITA promoter for the controlling of MHC Class II expression &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b063">63</xref>&#x0005d;. The present demonstration that the pDC receptor BDCA2/Fc&#x0025b;RI&#x003b3; and BCR share the same membrane-proximal signaling cascade and pathway leading to NF-&#x003ba;B activation provides further support for the intriguing relationship between pDCs and B lymphocytes.</p><p>A central mediator during B cell activation, BLNK, is phosphorylated by BCR activation on five tyrosine residues (Y72, Y84, Y96, Y178, and Y189) that serve as docking sites for recruiting downstream molecules &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b034">34</xref>,<xref ref-type="bibr" rid="pbio-0050248-b036">36</xref>&#x0005d;. Interestingly, in resting primary pDCs, we observed high levels of, if not saturating, phosphorylation of Y84 in BLNK, which is involved in PLC&#x003b3;2 activation &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b036">36</xref>&#x0005d;. Further examination of tyrosine phosphorylation on other residues of BLNK may shed light on the dynamic involvement of this key molecule in nucleating signaling components during BDCA2 activation.</p><p>A recent study reported that BDCA2 may serve as an alternative receptor, in addition to CD4, CXCR4, and CCR5 on human pDCs, for HIV via binding to gp120 &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b064">64</xref>&#x0005d;. Therefore, it is plausible that HIV uptake by BDCA2 negatively affects the ability of pDCs to mount type I IFN responses. Similarly, <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content> targets DC-specific C-type lectin DC-SIGN to infect DCs and to directly down-regulate DC-mediated immune responses &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b065">65</xref>&#x0005d;. Moreover, measles virus (MV) interacts with CD46, its cellular receptor on human monocytes, to specifically down-regulate IL-12 production, a mechanism causing MV-induced immunosuppression &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b066">66</xref>&#x0005d;. Therefore, BDCA2 may represent another example of antigen uptake receptors targeted by microbial ligands to negatively regulate cellular immunity.</p><p>Paradoxically, activation by antigens through the BCR triggers B cell proliferation, differentiation, and Ig and cytokine production, whereas crosslinking of BDCA2, which activates a similar BCR-like signaling pathway, fails to stimulate pDCs to proliferate or produce cytokines &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b010">10</xref>&#x0005d; (W. Cao, unpublished data), but rather inhibits the TLR-mediated responses. As multiple receptors on pDCs apparently use ITAM-based mechanisms to modulate type I IFN and cytokine responses during TLR activation &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b017">17</xref>,<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>,<xref ref-type="bibr" rid="pbio-0050248-b067">67</xref>&#x02013;<xref ref-type="bibr" rid="pbio-0050248-b070">70</xref>&#x0005d;, our findings will facilitate further investigations to determine how TLR activation is regulated in pDCs. Such mechanisms may provide opportunities for therapeutic interventions in autoimmune diseases, such as SLE &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b024">24</xref>&#x0005d;, Sj&#x000f6;gren syndrome &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b071">71</xref>,<xref ref-type="bibr" rid="pbio-0050248-b072">72</xref>&#x0005d;, polymyositis &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b073">73</xref>,<xref ref-type="bibr" rid="pbio-0050248-b074">74</xref>&#x0005d;, and psoriasis &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b075">75</xref>,<xref ref-type="bibr" rid="pbio-0050248-b076">76</xref>&#x0005d;, where the causative mechanisms might involve hyper-activation of pDCs.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Media, cell lines, and reagents.</title><p>RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin (Invitrogen; <ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com">http://www.invitrogen.com</ext-link>), and heat-inactivated 10&#x00025; FBS (Atlanta Biologicals; <ext-link ext-link-type="uri" xlink:href="http://www.atlantabio.com">http://www.atlantabio.com</ext-link>) were used for the cell culture. The human acute T cell leukemia cell line Jurkat and the Burkitt lymphoma cell line Namalwa were purchased from the American Type Culture Collection (ATCC). The mouse 2B4 T hybridoma cell line was generously provided by H. Arase, Osaka University, Japan. CpG ODN 2216 (GGGGGACGATCGTCGG-GGGG and CpG 2006 (TCGTCGTTTTGTCGT-TTTGTCGTT) (Qiagen; <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com">http://www.qiagen.com</ext-link>) and R848 (InVivogen; <ext-link ext-link-type="uri" xlink:href="http://www.invivogen.com">http://www.invivogen.com</ext-link>) were used for pDC stimulation.</p></sec><sec id="s4b"><title>Immune cell isolation and establishment of gene expression database.</title><p>The institutional review board for human research at the M.D. Anderson Cancer Center approved this study. Our gene expression database containing multiple types of immune cells isolated from human peripheral blood was established as described &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;. For this study, four peripheral leukocyte cell types were isolated simultaneously from buffy coats of individual healthy donors. Briefly, pDCs were positively selected from PBMC with anti-BDCA-4-coated microbeads and sorted by flow cytometry as CD3<sup>&#x02212;</sup>CD4<sup>&#x0002b;</sup>CD8<sup>&#x02212;</sup>CD11c<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD16<sup>&#x02212;</sup>CD19<sup>&#x02212;</sup>CD56<sup>&#x02212;</sup>. The remaining PBMCs were stained and individual cell types were sorted accordingly: B cells (CD4<sup>&#x02212;</sup>CD8<sup>&#x02212;</sup>CD11c<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD16<sup>&#x02212;</sup>CD19<sup>&#x0002b;</sup>CD56<sup>&#x02212;</sup>CD235a<sup>&#x02212;</sup>BDCA2<sup>&#x02212;</sup>), CD4<sup>&#x0002b;</sup> T cells (CD4<sup>&#x0002b;</sup>CD8<sup>&#x02212;</sup>CD11c<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD16<sup>&#x02212;</sup>CD19<sup>&#x02212;</sup>CD56<sup>&#x02212;</sup>CD235a<sup>&#x02212;</sup>BDCA2<sup>&#x02212;</sup>), and NK cells (CD3<sup>&#x02212;</sup>CD4<sup>&#x02212;</sup>CD8<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD19<sup>&#x02212;</sup>CD56<sup>&#x0002b;</sup>CD235a<sup>&#x02212;</sup>BDCA2<sup>&#x02212;</sup>).</p></sec><sec id="s4c"><title>Quantitative real-time PCR.</title><p>Total RNA extraction and quantitative real-time (RT)-PCR were performed as described &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;. Oligonucleotide primers used are listed in the <xref ref-type="supplementary-material" rid="pbio-0050248-st001">Table S1</xref> or described previously &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;.</p></sec><sec id="s4d"><title>Cloning and expression of BDCA2 and transmembrane adapters.</title><p>Full-length human BDCA2 was cloned from cDNAs generated from human peripheral blood pDCs by high-fidelity PCR using the following primers: sense, ATATGGATCCATGGTGCCTGAAGAA-GAGC and antisense, CTATGAATTCTTATATGT-AGATCTTCTTCATC. The BDCA2 cDNA was then cloned into the Bam HI and Eco RI sites of a lentiviral vector FG-30 &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b077">77</xref>&#x0005d;. Full-length cDNA encoding human Fc&#x0025b;RI&#x003b3;, DAP12, and DAP10, as described previously &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b031">31</xref>&#x0005d;, were subcloned into FG-30. An Fc&#x0025b;RI&#x003b3; mutant with Y-to-F substitution in the ITAM was prepared by PCR and cloned into the FG-30 lentiviral vector for gene transduction.</p></sec><sec id="s4e"><title>NFAT-GFP reporter cell assays.</title><p>Both BDCA2 and Fc&#x0025b;RI&#x003b3;, or each cDNA individually, were transduced into mouse 2B4 T hybridoma cells stably expressing an NFAT-GFP reporter construct &#x0005b;<xref ref-type="bibr" rid="pbio-0050248-b032">32</xref>&#x0005d;. Transfected cells were cultured at 10<sup>6</sup> cells/ml in the presence of 10 &#x003bc;g/ml of plate-bound anti-BDCA2 mAb AC144 (Miltenyi Biotec; <ext-link ext-link-type="uri" xlink:href="http://www.miltenyibiotec.com">http://www.miltenyibiotec.com</ext-link>) or purified IgG1 isotype-matched control mAb (eBioscience; <ext-link ext-link-type="uri" xlink:href="http://www.ebioscience.com">http://www.ebioscience.com</ext-link>) for 20 h and then analyzed for GFP expression by flow cytometry.</p></sec><sec id="s4f"><title>Cell surface biotinylation and protein immunoprecipitation.</title><p>2 &#x000d7; 10<sup>7</sup> cells that were pre-washed with phosphate-buffered saline (PBS) were incubated with 2 mM EZ-Link Sulfo-NHS-LC-Biotin (Pierce Biotechnology; <ext-link ext-link-type="uri" xlink:href="http://www.piercenet.com">http://www.piercenet.com</ext-link>) according to manufacturer's protocol. Cells were then washed 3 time with 100 mM glycine in 1&#x000d7; PBS, and lysed in Brij-NP-40 lysis buffer (0.875&#x00025; Brij 97, 0.125&#x00025; Nonidet P-40, 10 mM Tris base, pH 8.0, 150 mM NaCl plus protease inhibitors). Then the lysates were cleared by a spin at 10,000<italic>g</italic> for 10 min. The lysates were incubated with either control mouse IgG1 or anti-BDCA2 mAb conjugated to Protein G-Sepharose (Pierce Biotechnology) at 4 &#x000b0;C overnight. The sepharose beads were washed extensively with the lysis buffer before elution of the antigen with SDS sample buffer. Western blots were performed with rabbit anti- Fc&#x0025b;RI&#x003b3; antibody (gift from Dr. M-H Jouvin, BIDMC, Boston) and HRP-conjugated goat anti-rabbit IgG or HRP-labeled neutravidin (Pierce Biotechnology).</p></sec><sec id="s4g"><title>Western blot analysis of protein tyrosine phosphorylation and expression.</title><p>5 &#x000d7; 10<sup>5</sup> cells transfected with BDCA2 and Fc&#x0025b;RI&#x003b3; were incubated with control mouse IgG1 (eBioscience) or anti-BDCA2 mAb (Miltenyi Biotec), and then crosslinked with F(ab')<sub>2</sub> goat anti-mouse IgG (Jackson ImmunoResearch Lab; <ext-link ext-link-type="uri" xlink:href="http://www.jacksonimmuno.com">http://www.jacksonimmuno.com</ext-link>). BCR crosslinking was performed by adding 15 &#x003bc;g/ml F(ab')<sub>2</sub> goat anti-human Ig (Southern Biotech). 5 &#x000d7; 10<sup>5</sup> pDCs isolated using a BDCA-4 cell isolation kit (Miltenyi Biotec) were incubated with control mouse IgG1, anti-BDCA2, or anti-BDCA-4 mAb (Miltenyi Biotec). Western blot was performed with anti-phospho Src family Ab, anti-phospho Syk Ab, anti-phospho Erk1/2, anti-non-phospho Src family Ab, anti-Syk Ab (Cell Signaling Technology; <ext-link ext-link-type="uri" xlink:href="http://www.cellsignal.com">http://www.cellsignal.com</ext-link>), anti-phospho BLNK, anti-phospho Vav1 (Abcam; <ext-link ext-link-type="uri" xlink:href="http://www.abcam.com">http://www.abcam.com</ext-link>), anti-phospho PLC&#x003b3;2 (BD Biosciences; <ext-link ext-link-type="uri" xlink:href="http://www.bdbiosciences.com">http://www.bdbiosciences.com</ext-link>), and anti-&#x003b2;-actin mAb (Sigma; <ext-link ext-link-type="uri" xlink:href="http://www.sigmaaldrich.com">http://www.sigmaaldrich.com</ext-link>).</p></sec><sec id="s4h"><title>Calcium influx assay.</title><p>10<sup>6</sup> transfected cells or pDCs, pre-loaded with Fluo4- and Fura Red-AM (Invitrogen), were crosslinked as described above and analyzed on a FACSAria (BD Biosciences) and data were evaluated by using FlowJo software (TreeStar; <ext-link ext-link-type="uri" xlink:href="http://www.treestar.com">http://www.treestar.com</ext-link>). As indicated, cells were pre-incubated for 30 min with 25 &#x003bc;M PP2, 25 &#x003bc;M PP3, or 5 &#x003bc;M Syk inhibitor (EMD Biosciences; <ext-link ext-link-type="uri" xlink:href="http://www.emdbiosciences.com">http://www.emdbiosciences.com</ext-link>) prior to crosslinking.</p></sec><sec id="s4i"><title>Namalwa transfectants.</title><p>Namalwa cells were transduced sequentially by lentiviral vectors expressing human IRF7, BDCA2, and Fc&#x0025b;RI&#x003b3;. Full-length human IRF7 was cloned from cDNAs generated from purified human peripheral pDCs using a high-fidelity Taq polymerase (Invitrogen) with primers; sense, ACCTCTAGAATGGCCTTGGCTCCTGAGAGG, and antisense, ATTCTCGAGCTAGGCGGGCTGCTCCAGCTCC. The transduced Namalwa cells were stimulated with CpG ODN 2006 and then cultured in the presence of 10 &#x003bc;g/ml of plate-bound anti-BDCA2 mAb AC144, F(ab')<sub>2</sub> goat anti-human Ig, or purified control IgG1 for 20 h. Supernatants were analyzed for cytokine secretion by ELISA using a human IFN&#x003b1; kit (Bender MedSystems; <ext-link ext-link-type="uri" xlink:href="http://www.bendermedsystems.com">http://www.bendermedsystems.com</ext-link>) and IL-10 kit (R&#x00026;D Systems; <ext-link ext-link-type="uri" xlink:href="http://www.rndsystems.com">http://www.rndsystems.com</ext-link>).</p></sec><sec id="s4j"><title>BDCA2 crosslinking on pDCs in culture.</title><p>5 &#x000d7; 10<sup>4</sup> pDCs isolated by enrichment with anti-BDCA-4&#x02013;coated microbeads and subsequent flow cytometry (CD4<sup>&#x0002b;</sup>CD11c<sup>&#x02212;</sup>CD3<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD16<sup>&#x02212;</sup>CD19<sup>&#x02212;</sup>CD56<sup>&#x02212;</sup>) were incubated with 5 &#x003bc;g/ml anti-BDCA2 or control mAb in 100 &#x003bc;l culture medium for 30 min prior to stimulation with 1 &#x003bc;M CpG 2216 or 0.05 &#x003bc;g/ml of R848. Cells and supernatants were harvested 18 h later for real-time quantitative PCR analysis and enzyme-linked immunosorbent assay (ELISA) using a human IFN&#x003b1; kit (Bender MedSystems), IFN&#x003b1; kit (PBL Biomedical Laboratories; <ext-link ext-link-type="uri" xlink:href="http://www.interferonsource.com">http://www.interferonsource.com</ext-link>), IL-6 kit, TNF&#x003b1; kit, CXCL10 kit, CCL3 kit, and CCL4 kit (R&#x00026;D Systems). For kinetic studies, pDCs were stimulated with 1 &#x003bc;M CpG 2216 and co-cultured with anti-BDCA2 or control mAbs at time 0. At different time points, supernatants were harvested for quantitation of cytokines or IFN by ELISA. Alternatively, CpG was added first to pDC cultures, and then anti-BDCA2 or control mAbs were added at different times thereafter. Eighteen h after addition of CpG, supernatants were harvested for quantitation of cytokines or IFN by ELISA.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pbio-0050248-sg001"><label>Figure S1</label><caption><title>Expression Levels of BDCA2 in the Presence and Absence of Fc&#x0025b;RI&#x003b3; on Transfected T Cells (Mouse 2B4 T Hybridoma and Human Jurkat Cell Lines) and Transfected B Cells (Human HPB-Null Cell Line)</title><p>(79 KB PPT)</p></caption><media xlink:href="pbio.0050248.sg001.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-sg002"><label>Figure S2</label><caption><title>Relative Transcription of Intracellular Molecules Involved in Antigen Receptor Signaling in Four Lymphoid Cell Types Based on Microarray Gene Expression Analysis</title><p>(57 KB PPT)</p></caption><media xlink:href="pbio.0050248.sg002.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-sg003"><label>Figure S3</label><caption><title>Blocking of Tyrosine Phosphorylation of BCR-Like Intracellular Signaling Components Induced by BDCA2 Crosslinking by Inhibitors of Src PTK or Syk in Freshly Isolated pDCs</title><p>(276 KB PDF)</p></caption><media xlink:href="pbio.0050248.sg003.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-sg004"><label>Figure S4</label><caption><title>Crosslinking of BDCA2 Inhibits TLR-Induced IFN&#x003b2; but Not Chemokine Production</title><p>Purified pDCs were stimulated by CpG following anti-BDCA2 or control Ab crosslinking. The amounts of secreted IFN&#x003b2;, CXCL10/IP-10, CCL3/MIP-1&#x003b1; and CCL4/MIP-1&#x003b2; from a representative donor (<italic>n</italic> &#x02265; 3) are shown.</p><p>(49 KB PPT)</p></caption><media xlink:href="pbio.0050248.sg004.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-sg005"><label>Figure S5</label><caption><title>Purified pDCs Were Co-Stimulated by CpG and mAbs (Anti-BDCA2 or Control IgG) for 4 or 8 Hours</title><p>The relative amounts of the secreted IFN&#x003b1; from four donors are shown. The median expression is marked by a horizontal bar. The numbers on top of the symbols indicate the average amounts of IFN&#x003b1; (pg/ml) present in the culture supernatant.</p><p>(44 KB PPT)</p></caption><media xlink:href="pbio.0050248.sg005.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-sg006"><label>Figure S6</label><caption><title>Relative Transcription of Intracellular Molecules Involved in NF-&#x003ba;B Activation in Peripheral Immune Cells Based on Microarray Gene Expression Analysis</title><p>(49 KB PPT)</p></caption><media xlink:href="pbio.0050248.sg006.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pbio-0050248-st001"><label>Table S1</label><caption><title>Oligonucleotide Primers Used</title><p>(26 KB DOC)</p></caption><media xlink:href="pbio.0050248.st001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors are grateful to Karen Ramirez, Zhiwei He, and Eric Wieder for cell sorting and technical support. We also thank Dr. Xiaofeng Qin for help on lentivirus constructions. LLL is an American Cancer Society Research Professor. DBR is supported by a Genentech Graduate Student Fellowship and a UCSF Chancellor's Research Fellowship.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>BCR</term><def><p>B cell receptor</p></def></def-item><def-item><term>BDCA2</term><def><p>blood dendritic cell antigen 2</p></def></def-item><def-item><term>CLR</term><def><p>C-type lectin receptor</p></def></def-item><def-item><term>DC</term><def><p>dendritic cell</p></def></def-item><def-item><term>DCIR</term><def><p>dendritic cell immunoreceptor</p></def></def-item><def-item><term>GFP</term><def><p>green fluorescent protein</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>ITAM</term><def><p>immunoreceptor-based tyrosine activation motif</p></def></def-item><def-item><term>mAb</term><def><p>monoclonal antibody</p></def></def-item><def-item><term>mDC</term><def><p>myeloid DC</p></def></def-item><def-item><term>NFAT</term><def><p>nuclear factor of activated T cells</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p>nuclear factor &#x003ba;B</p></def></def-item><def-item><term>NK cell</term><def><p>natural killer cell</p></def></def-item><def-item><term>pDC</term><def><p>plasmacytoid DC</p></def></def-item><def-item><term>PTK</term><def><p>protein tyrosine kinase</p></def></def-item><def-item><term>TCR</term><def><p>T cell receptor</p></def></def-item><def-item><term>TLR</term><def><p>Toll-like receptor</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pbio-0050248-b001"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><year>2001</year><article-title>Dendritic cells: Specialized and regulated antigen processing machines</article-title><source>Cell</source><volume>106</volume><fpage>255</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">11509172</pub-id></citation></ref><ref id="pbio-0050248-b002"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><year>1998</year><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><volume>392</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">9521319</pub-id></citation></ref><ref id="pbio-0050248-b003"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>R</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>Dendritic cells: Translating innate to adaptive immunity</article-title><source>Curr Top Microbiol Immunol</source><volume>311</volume><fpage>17</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">17048704</pub-id></citation></ref><ref id="pbio-0050248-b004"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geijtenbeek</surname><given-names>TBH</given-names></name><name><surname>van Vliet</surname><given-names>SJ</given-names></name><name><surname>Engering</surname><given-names>A</given-names></name><name><surname>t Hart</surname><given-names>BA</given-names></name><name><surname>van Kooyk</surname><given-names>Y</given-names></name></person-group><year>2004</year><article-title>Self- and nonself-recognition by C-type lectins on dendritic cells</article-title><source>Annu Rev Immunol</source><volume>22</volume><fpage>33</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15032573</pub-id></citation></ref><ref id="pbio-0050248-b005"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambi</surname><given-names>A</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><year>2003</year><article-title>Dual function of C-type lectin-like receptors in the immune system</article-title><source>Curr Opin Cell Biol</source><volume>15</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">14519388</pub-id></citation></ref><ref id="pbio-0050248-b006"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudziak</surname><given-names>D</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Heidkamp</surname><given-names>GF</given-names></name><name><surname>Buchholz</surname><given-names>VR</given-names></name><name><surname>Trumpfheller</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>Differential antigen processing by dendritic cell subsets in vivo</article-title><source>Science</source><volume>315</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">17204652</pub-id></citation></ref><ref id="pbio-0050248-b007"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name></person-group><year>2004</year><article-title>Plasmacytoid dendritic cells in immunity</article-title><source>Nature Immunol</source><volume>5</volume><fpage>1219</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">15549123</pub-id></citation></ref><ref id="pbio-0050248-b008"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y-J</given-names></name></person-group><year>2005</year><article-title>IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors</article-title><source>Annu Rev Immunol</source><volume>23</volume><fpage>275</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">15771572</pub-id></citation></ref><ref id="pbio-0050248-b009"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzionek</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>P</given-names></name><name><surname>Cremer</surname><given-names>S</given-names></name><name><surname>Zysk</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood</article-title><source>J Immunol</source><volume>165</volume><fpage>6037</fpage><lpage>6046</lpage><pub-id pub-id-type="pmid">11086035</pub-id></citation></ref><ref id="pbio-0050248-b010"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzionek</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon a/b induction</article-title><source>J Exp Med</source><volume>194</volume><fpage>1823</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">11748283</pub-id></citation></ref><ref id="pbio-0050248-b011"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>N</given-names></name></person-group><year>2007</year><article-title>Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen-presenting cells</article-title><source>J Derm Sci</source><volume>45</volume><fpage>77</fpage><lpage>86</lpage></citation></ref><ref id="pbio-0050248-b012"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Antonenko</surname><given-names>S</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name><etal/></person-group><year>2001</year><article-title>Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens</article-title><source>J Exp Med</source><volume>194</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">11561001</pub-id></citation></ref><ref id="pbio-0050248-b013"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Napolitani</surname><given-names>G</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells</article-title><source>Eur J Immunol</source><volume>31</volume><fpage>3388</fpage><lpage>3393</lpage><pub-id pub-id-type="pmid">11745357</pub-id></citation></ref><ref id="pbio-0050248-b014"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Rothenfusser</surname><given-names>S</given-names></name><name><surname>Britsch</surname><given-names>S</given-names></name><name><surname>Krug</surname><given-names>A</given-names></name><name><surname>Jahrsdorfer</surname><given-names>B</given-names></name><etal/></person-group><year>2002</year><article-title>Quantitative expression of toll-like receptor 1&#x02013;10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides</article-title><source>J Immunol</source><volume>168</volume><fpage>4531</fpage><lpage>4537</lpage><pub-id pub-id-type="pmid">11970999</pub-id></citation></ref><ref id="pbio-0050248-b015"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Innate immune recognition of viral infection</article-title><source>Nat Immunol</source><volume>7</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">16424890</pub-id></citation></ref><ref id="pbio-0050248-b016"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><year>2005</year><article-title>Regulation of the type I IFN induction: a current view</article-title><source>Int Immunol</source><volume>17</volume><fpage>1367</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">16214811</pub-id></citation></ref><ref id="pbio-0050248-b017"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y-J</given-names></name></person-group><year>2007</year><article-title>Innate immune functions of plasmacytoid dendritic cells</article-title><source>Curr Opin Immunol</source><volume>19</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">17113765</pub-id></citation></ref><ref id="pbio-0050248-b018"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Stetson</surname><given-names>DB</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Antiviral defense: Interferons and beyond</article-title><source>J Exp Med</source><comment>jem.20061377.</comment></citation></ref><ref id="pbio-0050248-b019"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Yoneyama</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Cell type-specific involvement of RIG-I in antiviral response</article-title><source>Immunity</source><volume>23</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">16039576</pub-id></citation></ref><ref id="pbio-0050248-b020"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H-H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Seth</surname><given-names>RB</given-names></name><etal/></person-group><year>2006</year><article-title>The specific and essential role of MAVS in antiviral innate immune responses</article-title><source>Immunity</source><volume>24</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">16713980</pub-id></citation></ref><ref id="pbio-0050248-b021"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baechler</surname><given-names>EC</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name></person-group><year>2004</year><article-title>The emerging role of interferon in human systemic lupus erythematosus</article-title><source>Curr Opin Immunol</source><volume>16</volume><fpage>801</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">15511676</pub-id></citation></ref><ref id="pbio-0050248-b022"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>J</given-names></name><name><surname>Tluk</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>C</given-names></name><name><surname>Hamm</surname><given-names>S</given-names></name><name><surname>Jurk</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8</article-title><source>J Exp Med</source><volume>202</volume><fpage>1575</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">16330816</pub-id></citation></ref><ref id="pbio-0050248-b023"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Means</surname><given-names>T</given-names></name><name><surname>Luster</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus</article-title><source>Ann N Y Acad Sci</source><volume>1062</volume><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">16461805</pub-id></citation></ref><ref id="pbio-0050248-b024"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>V</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>The central role of dendritic cells and interferon-alpha in SLE</article-title><source>Curr Opin Rheumatol</source><volume>15</volume><fpage>548</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">12960479</pub-id></citation></ref><ref id="pbio-0050248-b025"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzionek</surname><given-names>A</given-names></name><name><surname>Sohma</surname><given-names>Y</given-names></name><name><surname>Nagafune</surname><given-names>J</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon a/b induction</article-title><source>J Exp Med</source><volume>194</volume><fpage>1823</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">11748283</pub-id></citation></ref><ref id="pbio-0050248-b026"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzionek</surname><given-names>A</given-names></name><name><surname>Inagaki</surname><given-names>Y</given-names></name><name><surname>Okawa</surname><given-names>K</given-names></name><name><surname>Nagafune</surname><given-names>J</given-names></name><name><surname>R&#x000e8;ock</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Plasmacytoid dendritic cells: From specific surface markers to specific cellular functions</article-title><source>Hum Immunol</source><volume>63</volume><fpage>1133</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">12480257</pub-id></citation></ref><ref id="pbio-0050248-b027"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>N</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Miyachi</surname><given-names>Y</given-names></name></person-group><year>2004</year><article-title>Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2</article-title><source>Immunobiology</source><volume>209</volume><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">15481152</pub-id></citation></ref><ref id="pbio-0050248-b028"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>N</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Inaba</surname><given-names>K</given-names></name><name><surname>Lutz</surname><given-names>MB</given-names></name><name><surname>Miyachi</surname><given-names>Y</given-names></name></person-group><year>2004</year><article-title>Molecular cloning of human Dectin-2</article-title><source>J Invest Dermatol</source><volume>122</volume><fpage>1522</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">15175046</pub-id></citation></ref><ref id="pbio-0050248-b029"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>N</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Inaba</surname><given-names>K</given-names></name><name><surname>Miyachi</surname><given-names>Y</given-names></name></person-group><year>2003</year><article-title>Dendritic cell immunoactivating receptor, a novel C-type lectin immunoreceptor, acts as an activating receptor through association with Fc receptor g chain</article-title><source>J Biol Chem</source><volume>278</volume><fpage>32645</fpage><lpage>32652</lpage><pub-id pub-id-type="pmid">12777403</pub-id></citation></ref><ref id="pbio-0050248-b030"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>X-l</given-names></name><name><surname>Yudate</surname><given-names>T</given-names></name><name><surname>Chung</surname><given-names>J-S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor &#x003b3; chain to induce innate immune responses</article-title><source>J Biol Chem</source><volume>281</volume><fpage>38854</fpage><lpage>38866</lpage><pub-id pub-id-type="pmid">17050534</pub-id></citation></ref><ref id="pbio-0050248-b031"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Rosen</surname><given-names>DB</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Bover</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Plasmacytoid dendritic cell-specific receptor ILT7-FceRIg inhibits Toll-like receptor-induced interferon production</article-title><source>J Exp Med</source><volume>203</volume><fpage>1399</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">16735691</pub-id></citation></ref><ref id="pbio-0050248-b032"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arase</surname><given-names>H</given-names></name><name><surname>Mocarski</surname><given-names>ES</given-names></name><name><surname>Campbell</surname><given-names>AE</given-names></name><name><surname>Hill</surname><given-names>AB</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><year>2002</year><article-title>Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors</article-title><source>Science</source><volume>296</volume><fpage>1323</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">11950999</pub-id></citation></ref><ref id="pbio-0050248-b033"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>JE</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name></person-group><year>2003</year><article-title>Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling</article-title><source>Nat Immunol</source><volume>4</volume><fpage>1057</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">14586424</pub-id></citation></ref><ref id="pbio-0050248-b034"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koretzky</surname><given-names>GA</given-names></name><name><surname>Abtahian</surname><given-names>F</given-names></name><name><surname>Silverman</surname><given-names>MA</given-names></name></person-group><year>2006</year><article-title>SLP76 and SLP65: Complex regulation of signalling in lymphocytes and beyond</article-title><source>Nat Rev Immunol</source><volume>6</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16493428</pub-id></citation></ref><ref id="pbio-0050248-b035"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Iwamatsu</surname><given-names>A</given-names></name><name><surname>Gotoh</surname><given-names>K</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name></person-group><year>2000</year><article-title>BCAP: The tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation</article-title><source>Immunity</source><volume>13</volume><fpage>817</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">11163197</pub-id></citation></ref><ref id="pbio-0050248-b036"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C</given-names></name><name><surname>Dalton</surname><given-names>M</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>BLNK: Molecular scaffolding through 'cis'-mediated organization of signaling proteins</article-title><source>EMBO J</source><volume>21</volume><fpage>6461</fpage><lpage>6472</lpage><pub-id pub-id-type="pmid">12456653</pub-id></citation></ref><ref id="pbio-0050248-b037"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krieg</surname><given-names>AM</given-names></name><name><surname>Yi</surname><given-names>A-K</given-names></name><name><surname>Matson</surname><given-names>S</given-names></name><name><surname>Waldschmidt</surname><given-names>TJ</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name><etal/></person-group><year>1995</year><article-title>CpG motifs in bacterial DNA trigger direct B-cell activation</article-title><source>Nature</source><volume>374</volume><fpage>546</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">7700380</pub-id></citation></ref><ref id="pbio-0050248-b038"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henault</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>LN</given-names></name><name><surname>Evans</surname><given-names>GF</given-names></name><name><surname>Zuckerman</surname><given-names>SH</given-names></name></person-group><year>2005</year><article-title>The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides</article-title><source>J Immunol Methods</source><volume>300</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">15894327</pub-id></citation></ref><ref id="pbio-0050248-b039"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>M</given-names></name><name><surname>Lanier</surname><given-names>L</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Role of ITAM-containing adapter proteins and their receptors in the immune system and bone</article-title><source>Immunol Rev</source><volume>208</volume><fpage>50</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16313340</pub-id></citation></ref><ref id="pbio-0050248-b040"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><year>2000</year><article-title>Immune inhibitory receptors</article-title><source>Science</source><volume>290</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11021804</pub-id></citation></ref><ref id="pbio-0050248-b041"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><year>2003</year><article-title>Natural killer cell receptor signaling</article-title><source>Curr Opin Immunol</source><volume>15</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">12787756</pub-id></citation></ref><ref id="pbio-0050248-b042"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abram</surname><given-names>CL</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name></person-group><year>2007</year><article-title>The expanding role for ITAM-based signaling pathways in immune cells</article-title><source>Sci STKE</source><volume>2007</volume><fpage>re2</fpage><pub-id pub-id-type="pmid">17356173</pub-id></citation></ref><ref id="pbio-0050248-b043"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Inferences, questions and possibilities in Toll-like receptor signalling</article-title><source>Nature</source><volume>430</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">15241424</pub-id></citation></ref><ref id="pbio-0050248-b044"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Toll-like receptor function and signaling</article-title><source>J Allergy Clin Immunol</source><volume>117</volume><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">16675322</pub-id></citation></ref><ref id="pbio-0050248-b045"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasare</surname><given-names>C</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>Toll-like receptors: Linking innate and adaptive immunity</article-title><source>Microbes Infect</source><volume>6</volume><fpage>1382</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">15596124</pub-id></citation></ref><ref id="pbio-0050248-b046"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Martinez-Pomares</surname><given-names>L</given-names></name><name><surname>Stacey</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>HH</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><etal/></person-group><year>2005</year><article-title>Macrophage receptors and imune recognition</article-title><source>Ann Rev Immunol</source><volume>23</volume><fpage>901</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">15771589</pub-id></citation></ref><ref id="pbio-0050248-b047"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MJ</given-names></name><name><surname>Sancho</surname><given-names>D</given-names></name><name><surname>Slack</surname><given-names>EC</given-names></name><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Sousa</surname><given-names>CRe</given-names></name></person-group><year>2006</year><article-title>Myeloid C-type lectins in innate immunity</article-title><source>Nat Immunol</source><volume>7</volume><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">17110942</pub-id></citation></ref><ref id="pbio-0050248-b048"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>van Kooyk</surname><given-names>Y</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name></person-group><year>2002</year><article-title>C-type lectin receptors on dendritic cells and Langerhans cells</article-title><source>Nat Rev Immunol</source><volume>2</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">11910898</pub-id></citation></ref><ref id="pbio-0050248-b049"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fritz</surname><given-names>JH</given-names></name><name><surname>Ferrero</surname><given-names>RL</given-names></name><name><surname>Philpott</surname><given-names>DJ</given-names></name><name><surname>Girardin</surname><given-names>SE</given-names></name></person-group><year>2006</year><article-title>Nod-like proteins in immunity, inflammation and disease</article-title><source>Nat Immunol</source><volume>7</volume><fpage>1250</fpage><lpage>1257</lpage><pub-id pub-id-type="pmid">17110941</pub-id></citation></ref><ref id="pbio-0050248-b050"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name></person-group><year>2007</year><article-title>Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation</article-title><source>Nat Rev Immunol</source><volume>7</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17186029</pub-id></citation></ref><ref id="pbio-0050248-b051"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Kooyk</surname><given-names>Y</given-names></name><name><surname>Geijtenbeek</surname><given-names>TBH</given-names></name></person-group><year>2003</year><article-title>DC-SIGN: Escape mechanism for pathogens</article-title><source>Nat Rev Immunol</source><volume>3</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">12949494</pub-id></citation></ref><ref id="pbio-0050248-b052"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>NC</given-names></name><name><surname>Slack</surname><given-names>EC</given-names></name><name><surname>Edwards</surname><given-names>AD</given-names></name><name><surname>Nolte</surname><given-names>MA</given-names></name><name><surname>Schulz</surname><given-names>O</given-names></name><etal/></person-group><year>2005</year><article-title>Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins</article-title><source>Immunity</source><volume>22</volume><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">15845454</pub-id></citation></ref><ref id="pbio-0050248-b053"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>O</given-names></name><name><surname>Gewies</surname><given-names>A</given-names></name><name><surname>Finger</surname><given-names>K</given-names></name><name><surname>Schafer</surname><given-names>M</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity</article-title><source>Nature</source><volume>442</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">16862125</pub-id></citation></ref><ref id="pbio-0050248-b054"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Ishihara</surname><given-names>C</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Imanishi</surname><given-names>T</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors</article-title><source>Nat Immunol</source><volume>8</volume><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">17486093</pub-id></citation></ref><ref id="pbio-0050248-b055"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulze-Luehrmann</surname><given-names>J</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Antigen-receptor signaling to nuclear factor &#x003ba;B</article-title><source>Immunity</source><volume>25</volume><fpage>701</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">17098202</pub-id></citation></ref><ref id="pbio-0050248-b056"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thome</surname><given-names>M</given-names></name></person-group><year>2004</year><article-title>CARMA1, BCL-10 and MALT1 in lymphocyte development and activation</article-title><source>Nat Rev Immunol</source><volume>4</volume><fpage>348</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">15122200</pub-id></citation></ref><ref id="pbio-0050248-b057"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertin</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Srinivasula</surname><given-names>SM</given-names></name><name><surname>Jacobson</surname><given-names>MD</given-names></name><etal/></person-group><year>2000</year><article-title>CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B</article-title><source>J Biol Chem</source><volume>275</volume><fpage>41082</fpage><lpage>41086</lpage><pub-id pub-id-type="pmid">11053425</pub-id></citation></ref><ref id="pbio-0050248-b058"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernasconi</surname><given-names>NL</given-names></name><name><surname>Onai</surname><given-names>N</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year>2003</year><article-title>A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells</article-title><source>Blood</source><volume>101</volume><fpage>4500</fpage><lpage>4504</lpage><pub-id pub-id-type="pmid">12560217</pub-id></citation></ref><ref id="pbio-0050248-b059"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rissoan</surname><given-names>MC</given-names></name><name><surname>Duhen</surname><given-names>T</given-names></name><name><surname>Bridon</surname><given-names>JM</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N</given-names></name><name><surname>P&#x000e2;eronne</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells</article-title><source>Blood</source><volume>100</volume><fpage>3295</fpage><lpage>3303</lpage><pub-id pub-id-type="pmid">12384430</pub-id></citation></ref><ref id="pbio-0050248-b060"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bri&#x000e1;ere</surname><given-names>F</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N</given-names></name><name><surname>Delale</surname><given-names>T</given-names></name><name><surname>Burg</surname><given-names>S</given-names></name><name><surname>Corbet</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>Origin and filiation of human plasmacytoid dendritic cells</article-title><source>Human immunology</source><volume>63</volume><issue>12</issue><fpage>1081</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">12480251</pub-id></citation></ref><ref id="pbio-0050248-b061"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Reizis</surname><given-names>B</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>S-i</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><etal/></person-group><year>2004</year><article-title>Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin</article-title><source>Immunity</source><volume>21</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15345219</pub-id></citation></ref><ref id="pbio-0050248-b062"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schotte</surname><given-names>R</given-names></name><name><surname>Rissoan</surname><given-names>M-C</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N</given-names></name><name><surname>Bridon</surname><given-names>J-M</given-names></name><name><surname>Duhen</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development</article-title><source>Blood</source><volume>101</volume><fpage>1015</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">12393575</pub-id></citation></ref><ref id="pbio-0050248-b063"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Waldburger</surname><given-names>J-M</given-names></name><name><surname>e Sousa</surname><given-names>CR</given-names></name><name><surname>Acha-Orbea</surname><given-names>H</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name></person-group><year>2004</year><article-title>MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells</article-title><source>Nat Immunol</source><volume>5</volume><fpage>899</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">15322541</pub-id></citation></ref><ref id="pbio-0050248-b064"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname><given-names>E</given-names></name><name><surname>Cicala</surname><given-names>C</given-names></name><name><surname>Van Ryk</surname><given-names>D</given-names></name><name><surname>Goode</surname><given-names>DJ</given-names></name><name><surname>Macleod</surname><given-names>K</given-names></name><etal/></person-group><year>2007</year><article-title>HIV-1 gp120 inhibits TLR9-mediated activation and IFN-&#x003b1; secretion in plasmacytoid dendritic cells</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>3396</fpage><lpage>3401</lpage><pub-id pub-id-type="pmid">17360657</pub-id></citation></ref><ref id="pbio-0050248-b065"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geijtenbeek</surname><given-names>TBH</given-names></name><name><surname>van Vliet</surname><given-names>SJ</given-names></name><name><surname>Koppel</surname><given-names>EA</given-names></name><name><surname>Sanchez-Hernandez</surname><given-names>M</given-names></name><name><surname>Vandenbroucke-Grauls</surname><given-names>CMJE</given-names></name><etal/></person-group><year>2003</year><article-title>Mycobacteria target DC-SIGN to suppress dendritic cell function</article-title><source>J Exp Med</source><volume>197</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">12515809</pub-id></citation></ref><ref id="pbio-0050248-b066"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karp</surname><given-names>CL</given-names></name><name><surname>Wysocka</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>LM</given-names></name><name><surname>Ahearn</surname><given-names>JM</given-names></name><name><surname>Cuomo</surname><given-names>PJ</given-names></name><etal/></person-group><year>1996</year><article-title>Mechanism of suppression of cell-mediated immunity by measles virus</article-title><source>Science</source><volume>273</volume><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">8662504</pub-id></citation></ref><ref id="pbio-0050248-b067"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>JT</given-names></name><name><surname>Bieneman</surname><given-names>AP</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Chichester</surname><given-names>KL</given-names></name><name><surname>Vasagar</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>TLR9- and FceRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression</article-title><source>J Immunol</source><volume>175</volume><fpage>5724</fpage><lpage>5731</lpage><pub-id pub-id-type="pmid">16237063</pub-id></citation></ref><ref id="pbio-0050248-b068"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>N</given-names></name><name><surname>Allam</surname><given-names>J-P</given-names></name><name><surname>Hagemann</surname><given-names>T</given-names></name><name><surname>Jenneck</surname><given-names>C</given-names></name><name><surname>Laffer</surname><given-names>S</given-names></name><etal/></person-group><year>2004</year><article-title>Characterization of FceRI-bearing CD123&#x0002b; blood dendritic cell antigen-2&#x0002b; plasmacytoid dendritic cells in atopic dermatitis</article-title><source>J Allergy Clin Immunol</source><volume>114</volume><fpage>364</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">15316517</pub-id></citation></ref><ref id="pbio-0050248-b069"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44</article-title><source>Blood</source><volume>106</volume><fpage>2076</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">15941912</pub-id></citation></ref><ref id="pbio-0050248-b070"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blasius</surname><given-names>AL</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Maldonado</surname><given-names>J</given-names></name><name><surname>Takai</surname><given-names>T</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12</article-title><source>Blood</source><volume>107</volume><fpage>2474</fpage><lpage>2476</lpage><pub-id pub-id-type="pmid">16293595</pub-id></citation></ref><ref id="pbio-0050248-b071"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottenberg</surname><given-names>J-E</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Lucchesi</surname><given-names>C</given-names></name><name><surname>Letourneur</surname><given-names>F</given-names></name><name><surname>Mistou</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><fpage>2770</fpage><lpage>2775</lpage><pub-id pub-id-type="pmid">16477017</pub-id></citation></ref><ref id="pbio-0050248-b072"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f6;vgren</surname><given-names>T</given-names></name><name><surname>Eloranta</surname><given-names>M-L</given-names></name><name><surname>Kastner</surname><given-names>B</given-names></name><name><surname>Wahren-Herlenius</surname><given-names>M</given-names></name><name><surname>Alm</surname><given-names>GV</given-names></name><etal/></person-group><year>2006</year><article-title>Induction of interferon-a by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sj&#x000f6;gren's syndrome autoantigen-associated RNA</article-title><source>Arthritis Rheum</source><volume>54</volume><fpage>1917</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">16729300</pub-id></citation></ref><ref id="pbio-0050248-b073"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>SA</given-names></name><name><surname>Pinkus</surname><given-names>JL</given-names></name><name><surname>Pinkus</surname><given-names>GS</given-names></name><name><surname>Burleson</surname><given-names>T</given-names></name><name><surname>Sanoudou</surname><given-names>D</given-names></name><etal/></person-group><year>2005</year><article-title>Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis</article-title><source>Ann Neuro</source><volume>57</volume><fpage>664</fpage><lpage>678</lpage></citation></ref><ref id="pbio-0050248-b074"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Proelss</surname><given-names>J</given-names></name><name><surname>Zahn</surname><given-names>S</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Type I interferon-associated skin recruitment of CXCR3&#x0002b; lymphocytes in dermatomyositis</article-title><source>Clin Exp Dermatol</source><volume>31</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">16716166</pub-id></citation></ref><ref id="pbio-0050248-b075"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nestle</surname><given-names>FO</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Tun-Kyi</surname><given-names>A</given-names></name><name><surname>Homey</surname><given-names>B</given-names></name><name><surname>Gombert</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Plasmacytoid predendritic cells initiate psoriasis through interferon-a production</article-title><source>J Exp Med</source><volume>202</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">15998792</pub-id></citation></ref><ref id="pbio-0050248-b076"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilliet</surname><given-names>M</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Geiges</surname><given-names>M</given-names></name><name><surname>Cozzio</surname><given-names>A</given-names></name><name><surname>Thurlimann</surname><given-names>W</given-names></name><etal/></person-group><year>2004</year><article-title>Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors</article-title><source>Arch Dermatol</source><volume>140</volume><fpage>1490</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">15611427</pub-id></citation></ref><ref id="pbio-0050248-b077"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>XF</given-names></name><name><surname>An</surname><given-names>DS</given-names></name><name><surname>Chen</surname><given-names>IS</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>2003</year><article-title>Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">12518064</pub-id></citation></ref></ref-list><fn-group><fn id="ack1" fn-type="con"><p><bold>Author contributions.</bold> WC conceived, designed, and performed the experiments. LZ analyzed the data. DRB and GW performed some experiments. LB and MB prepared reagents. WC, LLL, and YJL had extensive scientific discussion for this study and wrote the paper.</p></fn><fn id="ack2" fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was supported by the M.D. Anderson Cancer Foundation (YJL) and the National Institutes of Health grant AI068129 (DBR and LLL).</p></fn><fn id="ack3" fn-type="conflict"><p><bold>Competing interests.</bold> The authors have declared that no competing interests exist.</p></fn></fn-group></back></article> 